RPD
November 17, 2026

Brand New In Box: A $215M Priority Review Voucher that Arrowhead Pharmaceuticals bought but no longer need

Arrowhead Pharmaceuticals announced in early August that they were purchasing a rare pediatric disease Priority Review Voucher (PRV) for $215M. This was particularly notable because with few exceptions, PRVs are usually purchased by very large pharmaceutical companies and Arrowhead have a market cap today of approximately $6B which is much smaller than a traditional buyer of a PRV. They intended to utilize the PRV to get priority review for their upcoming supplemental New Drug Application (sNDA) for plozasiran, to expand the approved indication to include patients with severe hypertriglyceridemia (sHTG).

A couple months later on October 7th, they announced that they were accepted into the FDA Split Real Time Application Review (STAR) program. The STAR program is an FDA pilot program introduced in 2022 that applies to new efficacy indications to allow earlier patient access to treatments that address an unmet medical need.

The FDA will consider an application eligible for the STAR pilot program if each of the following criteria are met:

  1. Clinical evidence from adequate and well-controlled investigation(s) indicates that the drug may demonstrate substantial improvement on a clinically relevant endpoint(s) over available therapies.
  2. The application is for a drug intended to treat a serious condition with an unmet medical need.
  3. No aspect of the submission is likely to require a longer review time.
  4. There is no chemistry, manufacturing, or control information that would require a foreign manufacturing site inspection.

Arrowhead stated in their October 7th announcement that "once accepted into the STAR program, a supplemental application qualifies for a 6-month priority review compared to a 10-month standard review." So they bought a PRV to speed up the sNDA review timeline but then were accepted into the STAR program, so no longer need to redeem the PRV...right?

Well... one of the requirements to be in the STAR program in the first place is that the efficacy supplement application must qualify for priority review. So they would have received priority review anyway from the FDA, without being in the STAR program or needing to redeem a PRV.

But how would they know that they would be eligible for priority review, as that determination is made by the FDA at filing of the application. So if they wanted to guarantee a priority review I could see why they would explore using a PRV...right?

Well... Ionis Pharmaceuticals, Inc. received approval in June 2026 for Tryngolza (olezarsen) to reduce triglycerides and the risk of acute pancreatitis in adults with severe hypertriglyceridemia (sHTG). They received approval via priority review and Breakthrough Therapy designations and there is no current suggestion that a PRV was used. It may be unfair for me to use this as a precedent, as this was the first treatment with this indication so their priority review doesn't promise other treatments would receive the same treatment.

The Breakthrough Therapy designation with Ionis' application was interesting to me because whilst it does not guarantee priority review, I was curious how many indications that have Breakthrough Therapy designation actually get priority review. There have been 352 Center for Drug Evaluation and Research (CDER) applications approved with Breakthrough Therapy designation and 94% had priority review (potentially some of these used a PRV but I haven't checked for this analysis). Arrowhead had received Breakthrough Therapy designation for plozasiran in sHTG in December 2025, eight months before buying the PRV.

It's easy to read the tea leaves in hindsight but the leaves were pointing to a priority review for Arrowhead's application. I naturally have no insight to any discussions between Arrowhead and the FDA and they truly may have assumed they wouldn't achieve a priority review without purchase and use of a PRV.

So where does this leave Arrowhead now. They are on track for priority review for their application and they still have their PRV which they can use for something else or likely sell on (BNIB if you are interested).

‍

‍

References:

Track every
FDA Priority Review Voucher Program.

Stay updated
Thank you!
Oops! Something went wrong while submitting your email.

This webpage has been compiled from manually reviewing thousands of documents from the U.S. Securities and Exchange Commission (SEC), U.S. Food and Drug Administration (FDA), Federal Register, press releases and financial records. The information on this page has been compiled from publicly available sources only and does not include any undisclosed PRV issuances, transactions or redemptions.

Stay in the loop

News, analysis, and insights from the world of Priority Review Vouchers.

Thank you!
Oops! Something went wrong while submitting your email.